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Summary
We have analyzed the DNA binding properties of the
antitumor agent trabectedin (ET-743, Yondelis) and
different analogs, namely, ET-745, lacking the C21-
hydroxyl group, and ET-637, ET-594, ET-637-OBu, with
modifications at the trabectedin C domain, versus
their effects on cell cycle, apoptosis, and gene expres-
sion. ET-745 failed to bind DNA, highlighting the im-
portance of the C21-hydroxyl group for DNA binding.
Analogs ranked trabectedin >> ET-637 z ET-594 >
ET-637-OBu >> ET-745 for their DNA binding capacity;
ET-637 and ET-594 display very different biological ac-
tivities. Drugs were clustered in three major groups
showing high (trabectedin, ET-637), intermediate
(ET-637-OBu), and low (ET-594, ET-745) cytotoxic
activity and similar transcriptional profiling responses.
C21-hydroxyl-deficient analogs of the above-men-
tioned compounds showed a dramatic decrease in
biological activity. Our data suggest that trabectedin
interacts with an additional non-DNA target to raise
an effective antitumor response, and that this interac-
tion is favored through trabectedin-DNA complexes.
Introduction
Ecteinascidins (ETs) are a group of antitumor alkaloids
extracted from the mangrove Caribbean tunicate
*Correspondence: fmollin@usal.esEcteinascidia turbinata in the late 1960s. Among the var-
ious ETs, ET-743 (a.k.a. trabectedin) proved to be cyto-
toxic at very low doses in a wide variety of tumor cells.
This marine compound, registered under the trade
name of Yondelis (trabectedin), has a broad spectrum
of anticancer activity in vivo (soft tissue sarcoma cells
are particularly sensitive to its action [1]) and is currently
under Phase II clinical investigation for treatment of soft
tissue sarcoma; ovarian, breast, endometrial, prostate,
non-small cell lung cancers; and pediatric sarcomas
[2–5]. So far, the only well established target for ETs is
DNA. Trabectedin binds covalently to guanine residues
in the minor groove of the DNA double helix to bend the
molecule toward the major groove [6, 7]. At micromolar
concentrations, trabectedin has also been shown to in-
hibit topoisomerase I [8] and a number of transcription
factors, including nuclear transcription factor NF-Y [9],
and has been shown to induce microtubule disorganiza-
tion [10]. However, these effects are considered unlikely
to be relevant to the mechanism of action of trabecte-
din, as they are evidenced at drug concentrations that
exceed pharmacologically active concentrations (nM
range) by a factor of 100 or higher [11–13]. The forma-
tion of ternary complexes of drug, DNA, and a nucleotide
excision-repair protein that lead to DNA single-strand
breaks in transcribed genes, which, in turn, result in
eventual cell death, has been proposed as the major
mechanism of trabectedin action [2, 14, 15]. The antitu-
mor activity of trabectedin is achieved through two
major dose-dependent actions on cancer cells: (1) tran-
scription-dependent growth arrest with an accumula-
tion of cells in G2/M when used at a concentration of
1–10 nM, and (2) transcription-independent apoptosis
when used at a concentration of 10–100 nM [16]. These
cytostatic and proapoptotic activities of trabectedin re-
sult from the activation of two different signaling path-
ways [16].
Here, we investigate whether the DNA binding activity
of trabectedin plays a role in the biological actions of
this drug by analyzing the DNA binding features as
well as the cytostatic, proapoptotic, and transcriptional
profiling activities of a number of structurally related tra-
bectedin analogs, ET-594, ET-637, ET-637-OBu, and
ET-745 (Figure 1). Structure-activity relationship (SAR)
studies in the ET series have been limited so far, mainly
because of the small amount and low chemical diversity
of analogs biosynthetically produced. However, the re-
cently described synthesis of trabectedin [17, 18] and
novel biosynthetic procedures have allowed for the pro-
duction of different trabectedin analogs; therefore,
more detailed SAR studies can be established [19].
The complex structure of trabectedin is usually decon-
voluted into three parts. Subunits A and B represent
the two tetrahydroisoquinoline rings that are fused
into a monobridged pentacyclic skeleton. A third tetra-
hydroisoquinoline ring (subunit C) is linked to the A-B
core via a ten membered lactone bridge through a ben-
zylic sulfide linkage. Trabectedin binds to the minor
groove of DNA to establish a covalent link to the exocy-
clic 2-amino group of guanine residues [6, 20]. The
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group (N2-C21-OH). NMR and modeling studies have
revealed that the crosslinking of DNA by trabectedin
places the A and B subunits deep into the minor groove
on the 50 and 30 sides, respectively, of the alkylated G,
while the C subunit protrudes outside of the groove
and shows little contact with DNA [21, 22]. This C sub-
unit is perpendicularly oriented above the A-B core in
the DNA minor groove and may serve as a hook for trap-
ping proteins surrounding the drug-DNA complex. It
may also play an indirect role in DNA recognition by
constraining the architecture of the A-B skeleton and
therefore influencing the dynamics of the drug/DNA in-
teraction. However, the role of this portion of the trabec-
tedin molecule remains unclear, and we address this
issue here by using C-modified analogs. The com-
pounds studied here include ET-745, which just lacks
the key C21-hydroxyl group. The absence of the carbi-
nolamine function is expected to prevent the drug
from alkylating DNA. This analog is thus a good control
by which to study binding versus bonding to DNA. Three
additional compounds tested here share a common
structural characteristic, namely, the loss of the tetra-
hydroisoquinoline C subunit that is replaced with an
N-acetyl group (ET-637), a propionate ester (ET-637-
OBu), or a keto function (ET-594). These three com-
pounds thus provide excellent molecular tools by which
to dissect the role of the C subunit of trabectedin in DNA
recognition and guanine alkylation, and in the ensuing
biological activities, including cell cycle arrest, apopto-
sis, and gene profiling (transcriptome) activity.
Results
DNA Binding Properties of Distinct Trabectedin
Analogs
The interaction of trabectedin and its analogs with DNA
was investigated by using gel shift and footprinting as-
says to compare the extent of binding and sequence se-
lectivity. The compounds were incubated with a 2900 bp
DNA restriction fragment for 1 hr, and samples were
loaded on 1% agarose gels. As shown in Figure 2A, tra-
bectedin strongly reduced the electrophoretic mobility
Figure 1. Structures of Trabectedin and Analogs
The three domains, A-B-C, of the trabectedin molecule are depicted.
Compound ET-745 lacks the reactive C21-OH group (arrow), and
compounds ET-637-OBu, ET-637, and ET-594 are modified at the
C domain.Figure 2. DNA Binding Capacity of Different Trabectedin Analogs
(A) Gel shift assay showing covalent binding of ET compounds
(1–50 mM each) to a 2900 bp DNA fragment. The control lane
(DNA) contained no drug. Symbols ‘‘f’’ and ‘‘b’’ refer to the free
and drug bound DNA species, respectively.
(B) Sequence-selective binding by DNase I footprinting assays in
a 265 bp fragment. (Upper) DNase I footprinting with a 265 bp re-
striction fragment in the presence of graded drug concentrations
(in mM). Control lanes (0) contained no drug. Guanine-specific se-
quence markers obtained by treatment of the DNA with dimethyl-
sulfate followed by piperidine were run in the lanes marked ‘‘G.’’
The numbers on the left side of the gel refer to the standard num-
bering scheme for the nucleotide sequence of the DNA fragment.
(Lower) The inset depicts the effect of trabectedin on DNase I
cleavage at the 62–77 region from which the 16 bp oligonucleotide
was derived. The drug stimulates DNA cleavage at the sites pointed
out by arrows and protect the two juxtaposed AG/CT steps. The re-
active guanines G67 and G71 are indicated by an asterisk.
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fects. ET-745 completely failed to reduce the mobility
of DNA, even when tested at a concentration as high
as 50 mM. The other analogs induced DNA retardation,
but they were less potent than trabectedin. Assuming
that the extent of gel retardation is proportional to the
affinity of the drug for DNA and/or their DNA alkylation
potential, the drugs rank in the order: trabectedin >>
ET-637z ET-594 > ET-637-OBu >> ET-745. The level of
gel retardation could reflect the putative DNA alkylation
potential of the drugs because noncovalent DNA binding
drugs generally do not induce such a pronounced effect
on DNA migration during electrophoresis. In support of
this view, we found that ethanol precipitation of samples
to dissociate free drug from bound drug had no effect on
gel retardation; trabectedin-DNA complexes, precipi-
tated or not with ethanol, migrated at the same positions
(data not shown), suggesting that gel shifts reflected co-
valent binding to DNA. The above-described gel shift
data agreed with footprinting data (see below), and,
therefore, the two methods tend to validate the following
conclusions: (1) ET-745 does not bind to DNA, (2) ET-637
and ET-594 display similar potency in terms of DNA
binding, and (3) trabectedin exhibits superior DNA bind-
ing properties compared to the analogs.
Similar gel shift experiments were performed with
two other DNA fragments to confirm the previous ob-
servations in different DNA sequence contexts and to
improve the resolution of the DNA binding study, up
to the nucleotide level. On the one hand, we used a ra-
diolabeled 56 bp restriction fragment obtained upon
digestion of the plasmid pDB293-2 with BamHI and
HindIII. The results obtained with this DNA substrate
were consistent with those obtained with the long frag-
ment. The electrophoretic mobility of this DNA was not
affected by ET-745, whereas the other compounds
showed a dose-dependent effect (data not shown).
On the other hand, a short 16 bp oligonucleotide con-
taining two high-affinity binding sites for trabectedin
was selected from footprinting experiments (Figure
2B) and was used in subsequent gel shift assays. A
265 bp fragment showed a strong binding sequence
for trabectidin and analogs ET-637 and ET-594 around
nucleotide positions 60–70, with prominent sites of
DNase I-enhanced cleavage flanking the binding se-
quence (Figure 2B). ET-745 did not show any sign of
binding to DNA, whereas the other compounds clearly
interacted with this target sequence (data not shown).
This short 16 bp oligonucleotide, containing only two
juxtaposed binding sites (Figure 2B), was used for melt-
ing temperature (Tm) experiments to study the drug
effects on the duplex stability of the DNA. Under our ex-
perimental conditions, the melting temperature of the
oligonucleotide was 33ºC, and a very strong duplex sta-
bilizing effect was observed in the presence of trabec-
tedin, with a DTm (Tmdrug-DNA complex 2 TmDNA alone) of
up to 32ºC at a drug/DNA-nucleotide ratio of 0.1 (Figure
3A). The DTm values dropped with the analogs ET-637,
ET-594, and ET-637-Obu, and this is consistent with
their reduced DNA binding capacity (Figure 3B). ET-
745 showed no effect on the melting temperature of
DNA, further supporting its inability to alkylate DNA.
Similar Tm data were obtained with DNA from calf thy-
mus (data not shown).Sequence Selectivity in the DNA Binding Properties
of Distinct Trabectedin Analogs
It could be argued that the lower extent of binding seen
with the trabectedin analogs is not due to a reduced
binding capacity, but to a modified sequence selectivity.
Trabectedin has been previously reported to bind best to
sequences containing 50-AGC-30 triplets compared to 50-
AGT-30 triplets [7]. To investigate the sequence selectiv-
ity profile of the analogs, two types of experiments were
performed. First, we used a gel shift assay employing
a battery of 15-mer oligonucleotides having a common
50-ATAATAXXXATAATA-30/30-TATTATYYYTATTAT-50
motif and only differing by the nature of the central XXX/
YYY triplet. Second, the sequence preference was inves-
tigated by means of DNase I footprinting to localize drug
binding sites on long DNA fragments.
Gel shift assays performed with the XXX/YYY model
system included the central triplet motifs AGA/TCT,
CGA/TCG, GGA/TCC, GGC/GCC, CGG/CCG, GCG/CGC,
or GGG/CCC. Representative gels are shown in Figure
4A, and the intensity of the band corresponding to the
drug-DNA complex (bound) was compared to that of
the unbound DNA (free). For trabectedin, the target
oligonucleotides can be divided into four categories ac-
cording to the level of binding: high (>40% bound: GGC/
GCC and CGG/CCG), medium (20%–40% bound: GGA/
TCC, GGG/CCC, GCG/CGC), low (5%–20% bound:
AGA/TCT), and poor binding (<5% bound: CGA/TCG).
These observations are consistent with the known se-
quence preference of trabectedin [6]. ET-745 showed
Figure 3. Effect of Trabectedin Analogs in DNA Thermal Denatur-
ation
(A) Thermal denaturation curves for the 16 bp oligonucleotide (50-
CTTTAGTGAGGGTTAA-30$50-TTAACCCTCACTAAAG-30, 20 mM in
bases), derived from Figure 2B, in the absence (solid line) and pres-
ence of trabectedin at a drug-DNA (nucleotide) ratio of 0.1 (dotted
line) and 0.05 (dashed line).
(B) Variation in melting temperature (DTm) for the different drugs at
two drug-DNA(nucleotide) ratios, 0.1 (hatched bars) and 0.05 (black
bars). ET-745 shows no binding to DNA, and, therefore, DTm is 0.
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bectedin Analogs to DNA
(A) Gel shift assays for the binding of trabectedin and analogs to
a series of 15 bp oligonucleotides containing a central triplet motif
of variable sequence. Band intensities were quantified by densi-
tometry, and the average values from three independent experi-
ments are shown below each panel. –, no significant binding.
(B) Sequence-selective binding by DNase I footprinting assays in
a 176 bp fragment. (Upper) DNase I footprinting in the presence
of graded drug concentrations (in mM). Control tracks (0) contained
no drug. Guanine-specific sequence markers were run in the lanes
marked ‘‘G.’’ The numbers on the left side of the gels refer to the
standard numbering scheme for the nucleotide sequence of the
DNA fragment. Square brackets indicate the positions of inhibition
of DNase I cutting in the presence of the drugs. (Lower) Differential
cleavage plots comparing the susceptibility of the 176 bp fragmentalmost no binding to any of the target oligonucleotides.
ET-637 and ET-594 were found to bind much more
weakly than trabectedin, and these two compounds
behave similarly. In this gel shift assay, as well as in the
footprinting assay (see below), these two analogs lack-
ing the C subunit of trabectedin exhibited similar profiles
of DNA recognition. They both showed good binding to
the GGC/GCC- and GCG/CGC-containing oligonucleoti-
des and failed to bind to AGA/TCT or CGA/TCG. The pro-
file of ET-637-OBu is reminiscent of that of ET-637 and
ET-594, but its overall affinity is further reduced.
DNase I footprinting experiments were carried out
with two pieces of DNA: a 265-mer and a 176-mer re-
striction fragment. In both cases, the DNA substrate
was 30 end radiolabeled and subjected to limited cleav-
age by the endonuclease DNase I in the presence of
increasing concentrations of the ET compounds. The
products of degradation are then resolved by denatur-
ing gel electrophoresis. Typical gels are shown in Figure
4B for the 176-mer and Figure 2B for the 265-mer. Tra-
bectedin strongly affects the cleavage of DNA by the
enzyme. With both fragments, the drug induced a
pronounced dose-dependent increase in DNase I cleav-
age at several sites, such as around nucleotide posi-
tions 62 and 77 for the 265-mer (Figure 2B) and 55, 64,
and 77 for the 176-mer (Figure 4B). Adjoining these
sites, there were regions in which the cleavage by the
enzyme was reduced or inhibited, and these regions
corresponded to the drug binding sites (Figure 4B).
The sites of enhanced cleavage were particularly in-
tense and unusual for such a low-molecular weight
compound. Two independent effects might contribute
to the cleavage enhancement: redistribution of the en-
zyme at sites not occupied by the bound drug mole-
cules (the mass action effect), and drug-induced
structural changes of the DNA helix rendering the dou-
ble helix more susceptible to cutting by the enzyme. In
the present case, attribution of enhanced cleavage by
DNase I to a mass action effect is implausible because
it would lead to a general increase in cleavage. Thus,
drug-induced structural changes are the only plausible
explanation. In this regard, trabectedin induces DNA
bending and a widening of the DNA minor groove, which
could facilitate cleavage by the enzyme at locations sur-
rounding the drug binding sites [7]. Whatever the exact
origin of these enhancement sites is, they are very use-
ful for comparing the extent of binding of the analogs.
The sites of enhanced cleavage are much less pro-
nounced with ET-637 and ET-594, and they are virtually
absent with ET-637-OBu, compared to trabectedin.
With the 265-mer fragment, a detailed analysis of the re-
gion between nucleotide positions 62–77 indicated that
trabectedin, and to a lesser extent its analogs, protect
the two juxtaposed 50-AG-30 steps from DNase I
to DNase I cutting in the presence of the different drugs (10 mM
each). Negative values correspond to a ligand-protected site, and
positive values represent enhanced cleavage. Vertical scales are
in units of ln(fa) 2 ln(fc), where fa is the fractional cleavage at any
bond in the presence of the drug, and fc is the fractional cleavage
of the same bond in the control, given closely similar extents of
overall digestion. Only the region of the restriction fragment ana-
lyzed by densitometry is shown.
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1205Table 1. Dose Response and Time Course of the Effects of Trabectedin Analogs on Cell Cycle in HL-60 Cells
Treatment
24 hr 48 hr
Drug M Sub-G1 G0/G1 S G2/M Sub-G1 G0/G1 S G2/M
Control — 1.8 6 0.7 57.0 6 5.1 16.6 6 1.8 24.6 6 2.9 2.1 6 0.7 59.5 6 5.3 14.7 6 2.4 23.7 6 3.2
Trabectedin 1027 58.2 6 5.2 24.1 6 2.8 14.5 6 1.9 3.2 6 0.3 90.2 6 2.2 5.8 6 1.9 2.9 6 0.3 1.1 6 0.1
1028 49.3 6 4.7 26.4 6 2.3 13.2 6 1.3 11.1 6 1.0 85.6 6 3.2 9.4 6 2.3 3.2 6 0.3 1.8 6 0.7
1029 1.9 6 0.2 26.1 6 3.0 13.1 6 1.9 58.9 6 6.0 4.5 6 0.4 20.3 6 3.8 5.8 6 1.2 69.4 6 5.1
ET-637 1027 56.3 6 5.3 25.6 6 3.7 13.8 6 1.8 4.3 6 0.5 89.1 6 2.1 6.9 6 1.3 2.8 6 0.7 1.2 6 0.1
1028 48.6 6 4.5 27.1 6 2.2 11.7 6 1.2 12.6 6 1.2 83.4 6 3.4 10.6 6 2.0 3.1 6 0.8 2.9 6 0.6
1029 1.8 6 0.2 25.3 6 3.1 16.2 6 2.7 56.7 6 5.3 4.4 6 0.4 22.1 6 3.0 8.2 6 1.7 65.3 6 5.1
ET-637-OBu 1027 47.6 6 4.5 28.7 6 3.0 14.9 6 1.3 8.8 6 0.9 86.2 6 3.2 9.8 6 2.2 2.5 6 0.8 1.5 6 0.2
1028 6.7 6 0.9 16.9 6 2.6 8.9 6 1.9 67.5 6 5.1 26.8 6 2.3 19.2 6 1.8 10.7 6 1.0 43.3 6 3.1
1029 2.3 6 0.2 53 6 5.0 15.3 6 2.4 29.4 6 3.0 2.4 6 0.3 47.3 6 4.5 17.1 6 1.5 33.2 6 3.2
ET-594 1027 48.3 6 4.1 28.2 6 1.9 13.8 6 1.2 9.7 6 0.8 85.0 6 4.1 7.9 6 2.1 4.2 6 1.2 2.9 6 0.8
1028 1.5 6 0.2 42 6 3.6 18.2 6 1.6 38.3 6 3.6 10.3 6 1.0 50.8 6 4.1 14.5 6 1.3 24.4 6 2.2
1029 1.4 6 0.2 55.5 6 4.7 17.5 6 1.5 25.6 6 2.7 3.4 6 0.3 55.4 6 4.3 18.5 6 2.0 22.7 6 2.4
ET-745 1027 2.1 6 0.2 46.5 6 4.2 15.6 6 1.3 35.8 6 3.4 18.3 6 1.6 49.4 6 4.3 10.1 6 1.0 22.2 6 1.7
1028 2.0 6 0.2 56.3 6 5.3 15.2 6 1.3 26.5 6 2.3 6.8 6 0.9 60.1 6 5.1 9.9 6 1.8 23.2 6 2.5
1029 1.9 6 0.2 60.1 6 5.6 11.9 6 1.0 26.1 6 2.6 2.8 6 0.5 59.6 6 4.3 12.6 6 1.8 25.0 6 2.9
HL-60 cells were incubated with the indicated concentrations of the distinct trabectedin analogs for 24 and 48 hr, and the proportion of cells in
each phase of the cell cycle was quantitated by flow cytometry. Cells in the sub-G1 region represent apoptotic cells. Untreated control cells were
run in parallel. Most relevant increases in sub-G1 and G2/M are labeled in bold. Data are shown as means 6 SD of three independent
experiments.cleavage and strongly stimulate cutting at the flanking
sites. The drug apparently reacted with the G67 and
G71 residues (Figure 2B). With the 176-mer fragment,
the differential cleavage plots (obtained from the densi-
tometric analysis of the gels) indicate that the drugs
bind preferentially to several GC-rich sequences, such
as the exclusively GC sequence between positions 40
and 50. Here again, the analogs essentially recognize
the same sites as trabectedin, but with a reduced affin-
ity, and this is consistent with the above-mentioned Tm
and gel shift data.
Effects of the Distinct Trabectedin Analogs
on Cell Cycle and Apoptosis
Because trabectedin exerts two major biological effects
on tumor cells, namely, cell cycle arrest and apoptosis
[16], which account for the antitumor action of the
drug, we next investigated the capacity of the above-
described trabectedin analogs to promote cell cycle ar-
rest and apoptosis in a human leukemic cell line (HL-60
acute myeloid leukemia cells) and two human solid tu-
mor cell lines (HeLa cervix cancer cells and A459 lung
cancer cells) to draw general conclusions about cancer
cells. Surprisingly, we found that the biological activity
of the above-described trabectedin analogs did not
match their respective DNA binding abilities. Trabecte-
din induces a direct apoptotic response at 10 and 100
nM, whereas it arrests cells at G2/M at at 1 nM concen-
tration, eventually leading to cell death [16]. As shown in
Table 1, for HL-60 cells, trabectedin and ET-637 showed
a practically identical biological behavior, whereas
ET-594, which displayed almost identical DNA binding
properties to ET-637, was rather inactive at low concen-
trations (1 nM). ET-594 promoted an apoptotic response
only at high doses (100 nM), and it exerted a weak cell
cycle arrest effect at 10 nM. ET-745 was largely inactive,
and only some weak cell cycle and apoptotic responses
were achieved after protracted incubations with high
drug concentrations (100 nM). ET-637-OBu showed anintermediate cytotoxic activity, lower than ET-637 and
higher than ET-594 (Table 1). Similar results were ob-
tained with HeLa cells and A459 cells (data not shown).
Although there was some variability regarding the rela-
tive drug dose-response profiles to achieve cell cycle
arrest and apoptosis when using distinct cell lines
(data not shown), we found that all of the various com-
pounds assayed were able to induce both cell cycle
arrest and apoptosis. Thus, trabectedin and ET-637
promoted a direct apoptotic response in HL-60 and
HeLa cells when used at a 10 or 100 nM concentration,
and they also promoted a strong cell cycle arrest at G2/M
that eventually led to apoptosis when used at 1 nM
(Table 1, and data not shown). However, ET-637-OBu in-
duced both a direct apoptotic response and cell cycle-
mediated apoptosis when used at a concentration of
10 nM in the solid tumor cell lines (data not shown),
and it mostly induced G2/M arrest followed by apopto-
sis in HL-60 cells (Table 1). ET-594 required 10 nM (in
HL-60 and HeLa cells) and 100 nM (in A549 cells) con-
centrations to arrest cells in G2/M. ET-745 required
100 nM doses to arrest cells at G2/M in HL-60 and
HeLa cells (Table 1, and data not shown). Although
both cytostatic and apoptotic effects were observed
in all three of the human tumor cell lines assayed, lung
carcinoma A549 cells were more resistant, and higher
drug doses were required to achieve similar biological
effects to those detected in HL-60 and HeLa cells.
This suggests that the target(s) of trabectedin is(are)
present in the three cell lines studied here, but the sig-
naling pathways set off by the target(s) seem to be
more preponderant in some cells than in others, leading
to a variable response among the distinct cell lines.
Thus, cell type-specific downstream signaling events
could affect the final outcome of trabectedin action.
Overall, the biological data indicate that the drugs
rank in the order trabectedin z ET-637 > ET-637-OBu
>> ET-594 > ET-745 for their capacity to induce dose-
dependent cell cycle arrest and apoptosis.
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on JNK and Caspase-3 Activation
Because trabectedin-induced apoptosis involves c-Jun
NH2-terminal kinase (JNK) and caspase-3 activation
[16], we next examined the effect of the distinct trabec-
tedin analogs on these biochemical processes; assayed
the presence of phospho-JNK, through the use of a
monoclonal antibody specific for the phosphorylated
forms of JNK1/2; and assayed cleavage of the typi-
cal caspase-3 substrate poly(ADP-ribose) polymerase
(PARP), by using a polyclonal antibody that detected
both the 116 kDa intact form and the 85 kDa cleaved
form of PARP. The ability of the distinct trabectedin ana-
logs to activate JNK and caspase-3 followed the order
trabectedin z ET-637 > ET-637-OBu >> ET-594 R
ET-745 (Figures 5A and 5B). This order is in good corre-
lation with their relative effects on cell cycle arrest and
apoptosis. b-actin was used as an internal control; there
are equivalent protein amounts in each lane of the gels
shown in Figures 5A and 5B (data not shown). On the
other hand, neither trabectedin nor any of its analogs
herein studied induced extracellular signal-regulated ki-
nase (ERK) activation, assessed by the lack of any in-
crease in the basal level of phospho-ERK (data not
shown). In addition, neither trabectedin nor any of its
analogs induced any change in the protein level of
JNK or ERK (data not shown).
Relative Changes in Gene Expression Induced
by Distinct Trabectedin Analogs in Tumor Cells
We next investigated the effects of the trabectedin ana-
logs on gene expression by using oligonucleotide arrays.
A549 cells were treated with the different trabectedin
analogs (3 nM), and their respective actions on gene ex-
pression were compared to those of untreated cells (Fig-
ure 5C). At this low concentration, the drug cytotoxic
action was transcription dependent [16]. A comparison
of the overall transcriptional changes induced by the dis-
tinct analogs revealed that the distinct compounds could
be clustered into three groups, according to their similar-
ities on the respective induced gene expression profiles,
namely: (1) trabectedin and ET-637; (2) ET-637-OBu; and
(3) ET-594 and ET-745. Interestingly, this correlated well
with the respective biological activities of the trabectedin
analogs. A remarkable result from these microarray anal-
yses was that the biologically active compounds trabec-
tedin, ET-637, and ET-637-OBu affected the expression
of genes related to DNA damage, whereas the rather in-
active analogs ET-594 and ET-745 did not. In this regard,
the three biologically active compounds upregulated
1.8- to 2.6-fold the DNA repair genes XPC (xeroderma
pigmentosum complementation group C), GADD45
(growth arrest and DNA-damage-inducible), and DDB2
(damaged-DNA binding protein 2), whereas no effect
was observed with the inactive analogs; these changes
have been confirmed by quantitative RT-PCR (data not
shown).
Analogs Lacking the C21-OH Group Show
Reduced Biological Activity
Our data indicate that ET-745, with a molecular struc-
ture similar to that of trabectedin, but lacking the C21-
OH (Figure 1), fails to bind to DNA and shows a very
reduced cytotoxic activity compared to trabectedin.We then synthesized the C21-OH-deficient analogs of
ET-637, ET-637-OBu, and ET-594, named ET-639, ET-
637-OBu-C21(H), and ET-596, respectively, and ana-
lyzed their cytotoxic activities. As shown in Table 2,
the lack of the C21-OH group drastically reduced the cy-
totoxic activity of the parental drugs to similar values in
all three of the human tumor cell lines assayed. The less
active the parental compound is, the less effect the lack
of the C21-OH group on cytotoxicity has. In fact, the
Figure 5. Effect of Different Trabectedin Analogs on Biochemical
Apoptotic Parameters and Gene Expression
(A and B) HL-60 and HeLa cells were incubated with the distinct tra-
bectedin analogs at 10 nM for the times indicated and then ana-
lyzed for (A) JNK activation and (B) PARP degradation by
immunoblotting with anti-phospho-JNK and anti-PARP antibodies,
respectively. The migration positions of (A) phospho-JNK1/2 as
well as of full-length PARP and its cleavage product p85 are indi-
cated. Experiments shown are representative of the three that were
performed.
(C) Hierarchical clustering of gene expression data during treat-
ment of A549 cells with distinct trabectedin analogs. A549 cells
were treated with the indicated compounds (3 nM) for 8 hr, and
then processed for gene microarray analysis. Columns represent
individual genes, and rows represent the cell treatment with the in-
dicated drugs. The color of each square represents the median-
polished normalized ratio of gene expression in A549 cells treated
with the indicated drug relative to untreated A549 cells. Red indi-
cates gene expression above the median; blue, below the median;
white, equal to median. Branch lengths of the dendogram show the
degree of similarity between the gene expression profiles induced
by each drug.
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Cell Line
Compound C-21 HL-60 HeLa A549
Trabectedin OH 1.2 6 0.2 3 1029 2.3 6 0.3 3 1029 3.4 6 0.6 3 1028
ET-745 H 2.2 6 0.2 3 1026 2.6 6 0.2 3 1026 7.1 6 0.7 3 1026
ET-637 OH 2.4 6 0.3 3 1029 3.6 6 0.4 3 1029 5.2 6 0.6 3 1028
ET-639 H 2.3 6 0.2 3 1025 3.0 6 0.2 3 1026 8.8 6 1.0 3 1026
ET-637-OBu OH 7.1 6 0.8 3 1028 3.5 6 0.4 3 1027 7.8 6 0.8 3 1027
ET-637-OBu-C21(H) H 2.3 6 0.2 3 1025 1.4 6 0.1 3 1026 2.4 6 0.3 3 1025
ET-594 OH 1.2 6 0.3 3 1027 7.5 6 0.6 3 1027 2.3 6 0.2 3 1026
ET-596 H 2.9 6 0.3 3 1026 1.3 6 0.2 3 1026 4.1 6 0.6 3 1026
The presence of OH or H at C-21 is indicated. Values are IC50 in M and are shown as mean values 6 SD of six independent experiments.lack of the C21-OH group in the already poorly active
ET-594 compound has little effect on the cytotoxic ac-
tivity in both HeLa and A549 cells (Table 2).
Discussion
To our knowledge, this is the first structure-activity
study carried out with trabectedin analogs. The data re-
ported here demonstrate that the DNA interacting ability
of trabectedin is dramatically dependent on the C21-
OH, and changes in the C moiety of the trabectedin mol-
ecule affect DNA binding affinity. Thus, ET-745, lacking
the C21-OH, does not bind to DNA, and the other ana-
logs basically recognize the same sites as trabectedin
in DNA, preferentially GC-enriched sequences, but
with a lower affinity. Overall, the sequence selectivity
of trabectedin is essentially maintained with the differ-
ent analogs, although, in all cases, the modification of
the C domain has a modest but noticeable effect on
DNA sequence recognition. For example, trabectedin
binds more strongly to CGG sites compared to GCG,
whereas the opposite was observed with the N-acetyl
analog ET-637. According to NMR and molecular mod-
eling studies, the C domain of trabectedin is oriented
perpendicularly to the A-B core and protrudes outside
the double helix [21, 22]; however the 70-methoxy group
on the tetrahydroisoquinoline C domain could putatively
establish contact with a DNA base. Thus, modification
of the C domain might modulate the DNA binding ca-
pacity of the drug, either via the loss of a direct contact
or as a result of structural perturbation. Another possi-
bility is that the C domain markedly affects the kinetics
of the bonding reaction and/or the intrinsic stability of
the alkylated complex. We have found here that all
of the trabectedin analogs studied are able to induce
both cell cycle arrest and apoptosis in a dose-depen-
dent way, suggesting that both biological responses
are mediated through the extension at which the trabec-
tedin target(s) is(are) affected. The fact that ET-745, un-
able to bind DNA, can induce cell cycle arrest and
apoptosis in HL-60 and HeLa cells, although to
a much smaller efficiency than other DNA binding ana-
logs, suggests the existence of an additional non-DNA
target for trabectedin that eventually would signal
downstream events, leading to cell cycle arrest or apo-
ptosis. However, this putative, additional non-DNA tar-
get seems to be more efficiently affected through the
formation of a ternary complex together with the drug
and DNA. The finding that all of the C21-OH-deficientcompounds, which are thereby unable to bind to DNA,
show a poor cytotoxic activity suggests that interaction
of trabectedin with DNA is required to mount an opti-
mum biological response. It is interesting to note that
ET-637 and ET-594 show practically identical DNA bind-
ing properties but have very different cytotoxic and
transcriptional profiling activities, further suggesting
that additional non-DNA targets can play a role in tra-
bectedin antitumor action. These data suggest that
DNA is a necessary condition, but not sufficient, to raise
an effective apoptotic response. However, it cannot be
ruled out at present that ET-594 might be sequestered
by cell proteins, preventing its interaction with DNA
and thus leading to a minor biological response. On
the other hand, the earlier finding that protein synthesis
was required for trabectedin-induced cell cycle arrest
[16] suggests the involvement of a protein in the action
of this drug. Taken together, we can envision a hypo-
thetic model for the action of trabectedin that can be
used as a working hypothesis. This model would involve
the existence of two targets for trabectedin, namely,
DNA and a non-DNA target, likely a protein located
close to DNA. Trabectedin binding to DNA would facili-
tate and stabilize the interaction with this putative, sec-
ond non-DNA target, leading to the formation of a
ternary complex that eventually would trigger apoptosis
or cell cycle arrest. Failure to bind DNA would lead to
a much less effective response. Interestingly, trabecte-
din antitumor action is dependent on transcription when
used at low concentration [16], and we have found that
the analogs herein studied promote gene regulation
patterns that correlate very well with their correspond-
ing cytostatic and cytotoxic actions. A number of DNA
repair genes, including XPC, GADD45, and DDB2,
were upregulated by the biologically active analogs,
but not by the rather inactive analogs. This differential
expression of DNA repair genes could play an important
role in the antitumor action of this drug. In this regard,
trabectedin-induced tumor killing has been proposed
to be dependent upon transcription-coupled nucleo-
tide-excision repair [15]. The fact that trabectedin ana-
logs unable to bind DNA can still induce cell cycle
arrest and apoptosis in a number of tumor cell lines, al-
though with a much lower efficiency than DNA-interact-
ing analogs, suggests that the interaction of trabectedin
with a putative non-DNA target can lead to cytotoxicity.
This opens the possibility of searching for non-DNA-
interacting analogs that can induce apoptosis without
affecting the rather non-specific DNA target.
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mycin A shows remarkable structural similarities, as
well as a similar cytotoxic activity (in the nM range), to
trabectedin. The analysis of the genetic responses to
saframycin A treatment showed that this drug did not
affect the expression of known DNA-damage repair
genes, suggesting that the primary mechanism of action
of saframycin A may not involve known DNA-damage
pathways [23]. However, our proposed model for the
formation of a protein-DNA-trabectedin ternary com-
plex has found experimental support with the recent
findings by Xing et al. [24], who have shown that safra-
mycin A forms ternary complexes with GAPDH and DNA
and have identified GAPDH as a protein target of safra-
mycin A.
Significance
To our knowledge, the present work represents the
first structure-activity study with trabectedin analogs.
This has led us to conclude that: (1) the C21-hydroxyl
group is both essential for DNA binding and is impor-
tant for an optimum biological activity; (2) variations
in the C domain of the trabectedin molecule result
in modifications in both biological activity and DNA
binding capacity; and (3) trabectedin interaction with
DNA is necessary, but not sufficient, to mount an op-
timum biological response. Gel shift and DNase I foot-
printing assays with distinct DNA sequences showed
that the analogs ET-637 and ET-594, with different
modifications at the C domain of the trabectedin mol-
ecule, displayed similar DNA binding activities, but
had very different biological responses. Our data sug-
gest that trabectedin interacts with both DNA and an
additional non-DNA target to raise a potent antitumor
response, likely via its C domain. This latter interac-
tion with a putative non-DNA target could be greatly
favored by the formation of trabectedin-DNA com-
plexes. The C domain of trabectedin seems to play a
pivotal role, possibly by promoting molecular talk be-
tween DNA and the additional, yet unidentified target.
The interaction of trabectedin with this target could
mount a graded response, cell cycle arrest, or apopto-
sis. Although some analogs showed similar DNA
binding activities but distinct biological responses,
assessed as cell cycle arrest and induction of apopto-
sis, we found a remarkable correlation between bio-
logical responses and changes induced in gene
expression by the distinct trabectedin analogs. This
can provide potential clinical response markers on
the basis of gene expression changes in tumors. Our
present studies might set a framework for the design
of additional trabectedin analogs with improved anti-
tumor efficacy and/or reduced toxicity.
Experimental Procedures
Materials
Trabectedin and its analogs were provided by PharmaMar (Col-
menar Viejo, Madrid, Spain). The synthesis of trabectedin and its
analogs ET-745, ET-637, and ET-594 has been recently reported
[25]. The chemical synthesis of the other analogs used in the present
study will be described elsewhere.
DMEM and RPMI-1640 culture media, fetal calf serum (FCS), anti-
biotics, and L-glutamine were purchased from Life Technologies,Inc. (Gaithersburg, MD). Mouse monoclonal antibody C2.10 against
human PARP was purchased from Enzyme Systems Products (Liv-
ermore, CA). Anti-JNK1 (C-17) rabbit polyclonal antibody; mouse
monoclonal anti-phospho-JNK antibody G-7, raised against a pep-
tide corresponding to a short amino acid sequence containing
phosphorylated Thr-183 and Tyr-185 of human JNK; mouse mono-
clonal anti-phospho-ERK antibody E-4, raised against a short amino
acid sequenced containing phosphorylated Tyr-204 of human ERK
(identical to both ERK1 and ERK2); and mouse monoclonal anti-
ERK-2 antibody D-2, raised against a peptide mapping at the car-
boxy terminus of human ERK-2, were purchased from Santa Cruz
Biotechnology (Santa Cruz, CA). Acrylamide, bisacrylamide, ammo-
nium persulfate, and N,N,N0,N0-tetramethylethylenediamine were
purchased from Bio-Rad (Richmond, CA). All other chemicals
were purchased from Merck (Darmstadt, Germany) or Sigma.
Cell Culture
The human acute myeloid leukemia HL-60 cell line and the human
lung carcinoma A549 cell line were grown in RPMI-1640 supple-
mented with 10% (v/v) heat-inactivated FCS, 2 mM L-glutamine,
100 U/ml penicillin, 100 mg/ml streptomycin, and 24 mg/ml gentami-
cin. The human epitheloid cervix carcinoma HeLa cell line was
grown in DMEM culture medium supplemented with FCS and anti-
biotics as described above. Cells were incubated at 37ºC in a humid-
ified atmosphere of 5% CO2/95% air.
Cell Growth Inhibition Assay
Exponentially growing HeLa and A549 cells were seeded at 1.5 3
103/100 ml and 3 3 103/100 ml per well, respectively, in 96-well,
flat-bottomed microtiter plates, and they were incubated at 37ºC
in a humidified atmosphere of 5% CO2/95% air for 24 hr to let the
cells attach to the plates. HL-60 cells were seeded at 53 103 (100 ml)
cells per well. Then, cells were incubated with different drug con-
centrations at 37ºC under the 5% CO2/95% air atmosphere for
72 hr. Cell proliferation was quantified by using the XTT (sodium 30-
[1-(phenylamino-carbonyl)-3,4-tetrazolium]-bis (4-methoxy-6-nitro)
benzene sulfonic acid hydrate) cell proliferation kit (Roche Molecu-
lar Biochemicals, Mannheim, Germany) according to the manufac-
turer’s instructions. Briefly, a freshly prepared mixture solution of
XTT labeling reagent and PMS (N-methyl dibenzopyrazine methyl
sulfate) electron coupling reagent was added to each well in the
amount of 50 ml. The resulting mixtures were further incubated for
4 hr in a humidified atmosphere (37ºC, 5% CO2), and the absor-
bance of the generated formazan product was measured with a mi-
crotiter plate reader at a test wavelength of 490 nm and a reference
wavelength of 655 nm. IC50 (50% inhibitory concentration) was then
calculated as the drug concentration causing 50% inhibition in cell
proliferation.
Apoptosis
The induction of apoptosis was monitored by fluorescence flow cy-
tometry as the appearance of the sub-G1 peak in cell cycle analysis
[16] by using a Becton Dickinson FACSCalibur flow cytometer (San
Jose, CA). Quantitation of apoptotic cells was calculated as the per-
centage of cells in the sub-G1 region (hypodiploidy) in cell cycle
analysis.
Western Blot Analysis
About 107 cells were pelleted by centrifugation, washed with PBS,
lysed, and subjected to Western blot analysis as described previ-
ously [26]. Signals were developed by using an enhanced chemilu-
minescence (ECL) detection kit (Amersham Biosciences, Aylesbury,
UK). Immunoblotting with the mouse monoclonal anti-b-actin anti-
body AC15 (Sigma) was used as an internal loading control.
Thermal Denaturation Studies
The 16 bp double-stranded oligonucleotide (50-CTTTAGTGAGGGT
TAA-30 and its complementary strand, 20 mM) was incubated alone
(control Tm) or with 1 or 2 mM (drug:base ratio of 0.05 or 0.1) of the
various molecules in 1 ml BPE buffer (6 mM Na2HPO4, 2 mM
NaH2PO4, 1 mM EDTA [pH 7.1]). The absorbance at 260 nm was
measured every min over the range of 20ºC–90ºC with an increment
of 1ºC per min in 1 cm path length quartz cells by using a Uvikon 943
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The Tm values were determined from the first derivatives plots.
Gel Shift Experiments
These assays were carried out on agarose and acrylamide gels. A
2900 bp DNA fragment was obtained from BamHI digestion of plas-
mid pLAZ. DNA (130 ng) was incubated with the various drugs at
1–50 mM for 1 hr at room temperature in the binding buffer contain-
ing 10 mM Tris, 10 mM NaCl (pH 7.0) prior to electrophoresis on 1%
agarose gels (poststained with ethidium bromide). A 56 bp DNA
fragment was 30 end labeled by using a-[32P]-dATP and AMV re-
verse transcriptase for 2 hr at 37ºC prior to being purified on
a 10% native polyacrylamide gel as described in ‘‘DNase I Footprint-
ing.’’ To prepare the footprint oligonucleotide and the triplet-
containing double-stranded DNA targets for mobility shift assays
in acrylamide gels, a synthetic 16-mer oligonucleotide d(CTTTAGT
GAGGGTTAA) or various triplet-containing oligonucleotides and
their respective complementary strands were mixed at a 1:1 ratio,
heated to 75ºC, and slowly cooled to form duplexes, which were
then labeled at the 50 end by using g-[32P]-ATP and T4 polynucleo-
tide kinase. Labeled DNA was then purified by electrophoresis on
a 10% (w/v) polyacrylamide gel to remove the excess radioactive
nucleotide, cut out of the gel, and eluted overnight in 10 mM Tris
(pH 8.0), 1 mM EDTA, 100 mM NaCl. Samples were then ethanol pre-
cipitated, and the DNA pellet was dissolved in H2O. The typical
crosslinking reaction consisted of incubating 20,000 cpm radiola-
beled DNA with the test drug (15 mM each) for 1 hr at 37ºC in 20 ml
binding buffer (10 mM Tris [pH 7.0], 10 mM NaCl). After the addition
of 5 ml of a 50% glycerol solution containing tracking dyes, DNA
samples were resolved by electrophoresis under nondenaturing
conditions in 10% polyacrylamide gels for about 4 hr at 300V at
room temperature in TBE buffer (89 mM Tris base, 89 mM boric
acid, 2.5 mM Na2EDTA [pH 8.3]). Gels were transferred to Whatman
3 MM paper, dried under vacuum at 80ºC, and then analyzed on
a Molecular Dynamics 445SI phosphorimager (Molecular Dynamics,
Sunnyvale, CA).
DNase I Footprinting
The pTUC plasmid and the pBS plasmid were digested with PvuII-
EcoRI restriction enzymes, and the resulting 176 bp or 265 bp frag-
ments, respectively, were labeled at the 30 end (EcoRI site) with
a-[32P]-dATP and AMV reverse transcriptase. Electrophoresis on
a nondenaturing 6% (w/v) polyacrylamide gel was performed to re-
move the excess radioactive nucleotide, and the desired 30 end-
labeled product was cut out from the gel and eluted overnight in
10 mM Tris (pH 8.0), 1 mM EDTA, 100 mM NaCl. The DNA fragment
was then ethanol precipitated, and the DNA pellet was resuspended
in H2O. For the footprinting reactions, samples (3 ml) of the labeled
DNA fragment were incubated with 5 ml of the buffered solution con-
taining the various compounds at the indicated concentrations.
After 15 min of incubation at room temperature, the digestion was
initiated by the addition of 2 ml of a DNase I solution (final concentra-
tion 0.01 U/ml). After 3 min of incubation, the reaction was stopped
by freeze drying and lyophilization of the samples. The resulting
DNA pellet was resuspended in 5 ml of an 80% formamide solution
containing tracking dyes, heated at 90ºC for 4 min, and chilled in
ice for 4 min prior to electrophoresis on polyacrylamide gels under
denaturating conditions (8% acrylamide containing 8 M urea) in TBE
buffer. After electrophoresis, gels were soaked in 10% acetic acid
for 10 min, dried, and analyzed as described above.
Affymetrix Microarray Analysis
We analyzed RNA samples prepared from three independent ex-
periments for each experimental condition, namely, untreated and
treated with distinct trabectedin analogs at 3 nM. Total RNA was
isolated by using a RNeasy kit (Qiagen, Valencia, CA), and double-
stranded cDNA was synthesized from 15 mg total RNA by means
of the SuperScript double-stranded cDNA synthesis kit (Invitrogen,
San Diego, CA) with oligo(dT)24 primer containing T7 RNA polymer-
ase promoter. In vitro transcription was carried out as previously
described [16]. Microarray RNA analysis was performed according
to the manufacturer’s protocol with the Human Genome U133A
GeneChip (Affymetrix, Santa Clara, CA). Chips were stained and
washed with an Affymetrix fluids station and by following themanufacturer’s protocol. Chips were scanned with the HP Agilent
GeneArray Scanner, and values were normalized to a baseline array
with overall median intensity and were analyzed with the Affymetrix
Microarrays Suite 5.0 (MAS5.0) and GeneSpring 5.0 programs. Ar-
rays were scaled to an average intensity of 100 by using 1 as the
normalization factor and were analyzed independently by using
the untreated control samples as baselines. Only genes classified
as ‘‘present’’ were considered.
Statistical Analyses
Unless otherwise indicated, the results given are the mean (6SD) of
the number of experiments indicated.
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